drugset / Trial / NCT01578668
Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether erlotinib plus pemetrexed, cisplatin are effective and safe in treating lung adenocarcinoma with brain metastases.
Timeline
- Start
- 2012-01
- Primary completion
- 2015-01
- Completion
- 2015-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 20 mg/m2 | Intravenous |
| Subject | Cisplatin | Other / unclassified | 30 mg | Intravenous |
| Subject | Erlotinib | Small molecule | 150 mg | Oral |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |